PRF Technologies (PRFX) Total Current Liabilities (2019 - 2025)
PRF Technologies (PRFX) posted quarterly Total Current Liabilities of $2.4 million for Q4 2025, little changed year-on-year from $2.4 million in Q4 2024, and down 0.61% on a QoQ basis from $2.5 million in Q2 2025.
PRF Technologies (PRFX) Total Current Liabilities (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has reported Total Current Liabilities for 7 consecutive years, with $2.4 million the latest figure, recorded in Q4 2025.
- Quarterly Total Current Liabilities changed 0.04% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (changed 0.04% YoY) and the FY2025 annual result came in at $2.4 million, changed 0.04% from the prior year.
- Total Current Liabilities declined to $2.4 million in Q4 2025 per PRFX's latest filing, from $2.5 million in the prior quarter.
- Over the last five years, Total Current Liabilities for PRFX reached as high as $4.9 million in Q2 2024 and fell as low as $549000.0 in Q2 2022.
- A 5-year average of $1.5 million and a median of $1.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities plunged 91.08% — and 2024, when it soared 346.26%.
- Year by year, Total Current Liabilities stood at $757000.0 in 2021, then surged by 40.55% to $1.1 million in 2022, then sank by 37.5% to $665000.0 in 2023, then surged by 267.22% to $2.4 million in 2024, then retreated by 0.04% to $2.4 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $2.4 million, $2.5 million, and $2.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.44 Mn |
| Jun 30, 2025 | 2.46 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Jun 30, 2024 | 4.89 Mn |
| Mar 31, 2024 | 3.25 Mn |
| Dec 31, 2023 | 665,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.28 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 549,000.00 |
| Mar 31, 2022 | 768,000.00 |
| Dec 31, 2021 | 757,000.00 |
| Sep 30, 2021 | 628,000.00 |
| Jun 30, 2021 | 613,000.00 |
| Mar 31, 2021 | 741,000.00 |
| Dec 31, 2020 | 961,000.00 |
| Jun 30, 2020 | 6.87 Mn |
| Dec 31, 2019 | 6.34 Mn |